Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis
ClinicalTrials.gov Identifier:
NCT00467402
First received: April 27, 2007
Last updated: May 2, 2012
Last verified: May 2012
  Purpose

This study will demonstrate the efficacy of agomelatine (AGO178) 25 mg and 50 mg in the prevention of relapse in patients with Major Depressive Disorder (MDD). Eligible patients will undergo open-label treatment for 20 to 26 weeks, depending on response to treatment. Patients demonstrating stable response at the end of the open-label treatment phase will be assigned to receive agomelatine or placebo for 52 weeks.


Condition Intervention Phase
Major Depressive Disorder
Drug: agomelatine
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A 52-week, Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Study of the Long-term Efficacy, Tolerability and Safety of Agomelatine 25 and 50 mg in the Prevention of Relapse of Major Depressive Disorder (MDD) Following Open-label Treatment of 16-24 Weeks

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Time to relapse, where relapse is defined by the occurrence of any one of the following: [ Time Frame: Primary efficacy variable is measured from randomization to relapse ] [ Designated as safety issue: No ]
  • Hamilton Depression Rating Scale total score ≥16 at two consecutive visits; [ Time Frame: Primary efficacy variable is measured from randomization to relapse ] [ Designated as safety issue: No ]
  • hospitalization due to depression; [ Time Frame: Primary efficacy variable is measured from randomization to relapse ] [ Designated as safety issue: No ]
  • suicide attempt or suicide; [ Time Frame: Primary efficacy variable is measured from randomization to relapse ] [ Designated as safety issue: No ]
  • discontinuation due to lack of efficacy according to Investigator judgment. [ Time Frame: Primary efficacy variable is measured from randomization to relapse ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion of patients who demonstrate clinical improvement at the end of the double-blind continuation phase, where improvement is defined by a score of 1 or 2 on the Clinical Global Impression Improvement (CGI-I) scale. [ Time Frame: Secondary efficacy variables will be measured from randomization to the end of the Double-Blind continuation Phase ] [ Designated as safety issue: No ]
  • Proportion of patients experiencing relapse during the double-blind continuation phase. [ Time Frame: Secondary efficacy variables will be measured from randomization to the end of the Double-Blind continuation Phase ] [ Designated as safety issue: No ]
  • Proportion of patients who achieve remission at the end of the double-blind continuation phase, where remission is defined by a total score of ≤7 on the HAM-D. [ Time Frame: Secondary efficacy variables will be measured from randomization to the end of the Double-Blind continuation Phase ] [ Designated as safety issue: No ]
  • Change from randomization to the end of the double-blind continuation phase, on the Hospital Anxiety and Depression (HAD) total score and subscale scores. [ Time Frame: Secondary efficacy variables will be measured from randomization to the end of the Double-Blind continuation Phase ] [ Designated as safety issue: No ]

Enrollment: 644
Study Start Date: April 2007
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: agomelatine
Experimental: 2 Drug: agomelatine
Placebo Comparator: 3 Drug: placebo

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female adults, 18 through 70 years of age, inclusive
  • Diagnosis of Major Depressive Disorder, recurrent episode, according to Diagnostic and Statistical Manual of Mental Disorders - 4th Edition (DSM-IV) criteria
  • A history of at least two previous episodes of Major Depression plus the current episode
  • Hamilton Depression Rating Scale (HAM-D17) total score ≥ 22 at Screening and Baseline

Exclusion Criteria:

  • History of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating disorder, or obsessive compulsive disorder
  • Any current Axis I disorder other than major depressive disorder which is the focus of treatment
  • Substance or alcohol abuse in the last 30 days, dependence in the last 6 months
  • Use of any psychoactive medication after the screening visit
  • Patients who have been previously treated with agomelatine
  • Female patients of childbearing potential who are not using effective contraception

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00467402

  Hide Study Locations
Locations
United States, Alabama
Novartis Investigative Site
Birmingham, Alabama, United States, 35226
United States, Arizona
Novartis Investigative Site
Peoria, Arizona, United States, 85381
Novartis Investigative Site
Tucson, Arizona, United States, 85724
United States, California
Novartis Investigative Site
Beverly Hills, California, United States, 90210
Novartis Investigative Site
Costa Mesa, California, United States, 92626
Novartis Investigative Site
Encino, California, United States, 91316
Novartis Investigative Site
Glendale, California, United States, 91206
Novartis Investigative Site
Los Angeles, California, United States, 90024
Novartis Investigative Site
Newport Beach, California, United States, 92660
Novartis Investigative Site
Oceanside, California, United States, 92056
Novartis Investigative Site
Sacramento, California, United States, 95817
Novartis Investigative Site
Sherman Oaks, California, United States, 91403
Novartis Investigative Site
Temecula, California, United States, 92591
United States, Colorado
Novartis Investigative Site
Wheatridge, Colorado, United States, 80033
United States, Florida
Novartis Investigative Site
Bradenton, Florida, United States, 34208
Novartis Investigative Site
Coral Springs, Florida, United States, 33065
Novartis Investigative Site
Fort Myers, Florida, United States, 33912
Novartis Investigative Site
Gainsville, Florida, United States, 32607
Novartis Investigative Site
Jacksonville, Florida, United States, 32216
Novartis Investigative Site
St. Petersburg, Florida, United States, 33702
Novartis Investigative Site
Venice, Florida, United States, 34285
Novartis Investigative Site
West Palm Beach, Florida, United States, 33407
United States, Georgia
Novartis Investigative Site
Atlanta, Georgia, United States, 30328
United States, Illinois
Novartis Investigative Site
Chicago, Illinois, United States, 60611
Novartis Investigative Site
Chicago, Illinois, United States, 60640
Novartis Investigative Site
Libertyville, Illinois, United States, 60048
United States, Kansas
Novartis Investigative Site
Overland Park, Kansas, United States, 66211
Novartis Investigative Site
Topeka, Kansas, United States, 66606
United States, Louisiana
Novartis Investigative Site
New Orleans, Louisiana, United States, 70114
United States, Maryland
Novartis Investigative Site
Rockville, Maryland, United States, 20852
Novartis Investigative Site
Towson, Maryland, United States, 21204
Novartis Investigative Site
Towson, Maryland, United States, 85724
United States, Massachusetts
Novartis Investigative Site
Boston, Massachusetts, United States, 02135
Novartis Investigative Site
Braintree, Massachusetts, United States, 02184
Novartis Investigative Site
Worcester, Massachusetts, United States, 01605
United States, Michigan
Novartis Investigative Site
Farmington Hills, Michigan, United States, 48336
United States, Minnesota
Novartis Investigative Site
Minneapolis, Minnesota, United States, 55454
United States, Missouri
Novartis Investigative Site
Kansas City, Missouri, United States, 64111
Novartis Investigative Site
Kansas City, Missouri, United States, 66160
Novartis Investigative Site
St. Louis, Missouri, United States, 63033
Novartis Investigative Site
St. Louis, Missouri, United States, 63044
Novartis Investigative Site
St. Louis, Missouri, United States, 63118
United States, Nebraska
Novartis Investigative Site
Omaha, Nebraska, United States, 68198
United States, New Jersey
Novartis Investigative Site
Newark, New Jersey, United States, 07103
United States, New Mexico
Novartis Investigative Site
Albuquerque, New Mexico, United States, 87102
United States, New York
Novartis Investigative Site
Bronx, New York, United States, 10467
Novartis Investigative Site
Buffalo, New York, United States, 14215
Novartis Investigative Site
New York, New York, United States, 10029
Novartis Investigative Site
New York, New York, United States, 10021
United States, North Carolina
Novartis Investigative Site
Chapel Hill, North Carolina, United States, 27599
Novartis Investigative Site
Raleigh, North Carolina, United States, 27609
United States, Ohio
Novartis Investigative Site
Cleveland, Ohio, United States, 44195
Novartis Investigative Site
Columbus, Ohio, United States, 43210
Novartis Investigative Site
Toledo, Ohio, United States, 43623
United States, Oregon
Novartis Investigative Site
Portland, Oregon, United States, 97210
Novartis Investigative Site
Portland, Oregon, United States, 97239
Novartis Investigative Site
Rhododendron, Oregon, United States, 97049
United States, Pennsylvania
Novartis Investigative Site
Allentown, Pennsylvania, United States, 18104
Novartis Investigative Site
Lansdale, Pennsylvania, United States, 19446
Novartis Investigative Site
Philadelphia, Pennsylvania, United States, 19139
Novartis Investigative Site
Pittsburgh, Pennsylvania, United States, 15238
Novartis Investigative Site
Pittsburgh, Pennsylvania, United States, 15213
United States, South Carolina
Novartis Investigative Site
Charleston, South Carolina, United States, 29412
United States, Tennessee
Novartis Investigative Site
Memphis, Tennessee, United States, 38119
Novartis Investigative Site
Nashville, Tennessee, United States, 37212
United States, Texas
Novartis Investigative Site
Austin, Texas, United States, 78754
Novartis Investigative Site
Austin, Texas, United States, 78756
Novartis Investigative Site
DeSoto, Texas, United States, 75115
Novartis Investigative Site
Houston, Texas, United States, 77007
Novartis Investigative Site
Houston, Texas, United States, 77030
Novartis Investigative Site
Houston, Texas, United States, 77042
Novartis Investigative Site
Lake Jackson, Texas, United States, 77566
United States, Virginia
Novartis Investigative Site
Richmond, Virginia, United States, 23230
Novartis Investigative Site
Virginia Beach, Virginia, United States, 23230
United States, Washington
Novartis Investigative Site
Edmonds, Washington, United States, 98026
Novartis Investigative Site
Seattle, Washington, United States, 98104
United States, Wisconsin
Novartis Investigative Site
Milwaukee, Wisconsin, United States, 53226
Novartis Investigative Site
West Allis, Wisconsin, United States, 53227
Sponsors and Collaborators
Novartis
  More Information

No publications provided

Responsible Party: Novartis
ClinicalTrials.gov Identifier: NCT00467402     History of Changes
Other Study ID Numbers: CAGO178A2304
Study First Received: April 27, 2007
Last Updated: May 2, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:
agomelatine, Major Depressive Disorder, MDD, depression

Additional relevant MeSH terms:
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms
S 20098
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 22, 2014